Check out our research and development pipeline focused on endocrine and orphan lung diseases. Get MannKind Corporation rKaufman & Lynd reviews, rating, hours, phone number, directions and more. 1 Casper St Danbury, CT 06810-6903 VIEW MAP (203) 207-0912 www.mannkindcorp.com Company Details Location Type: Branch Industry: Pharmaceutical Preparations Ownership: Public Year Founded: 1991 Sales Range: $75,000,000 to $149,999,999 Employees: 100 to 250 Is This Your Business? Ms. Grancio will also serve as a member of the Audit Committee of the Board. Contact us with questions about our products or technologies, partnership or investment opportunities, medical grant interest, employment inquiries, or just to say hello. Est. Sign in. Chris Bosak / Hearst Connecticut Media Show More Show Less 6 of 6 Employers / Post Job. Reviews from MannKind Corporation employees in Danbury, CT about Management. Dr. Kay will also serve as a member of the Audit Committee of the Board. MannKind Corporation. Find company research, competitor information, contact details & financial data for Mannkind Corporation of Danbury, CT. Get the latest business insights from Dun & Bradstreet. Upload your resume. MannKind Corporation. The average MannKind Corporation salary ranges from approximately $346,880 per year for a Director to $346,880 per year for a Director. Willingness to travel up to 25% of the time MannKind Corporation Address Danbury, CT 06810 USA Industry Healthcare View all jobs at MannKind Corporation Report Job All Jobs Employee Communications Jobs 3 days ago. Contact - MannKind Corporation Make a humann connection. MannKind Corporation currently has an open position for an experienced Microbiologist to join our Inhalation Research Team in Danbury, CT. Sign in. Full-Time. Write a review. Computershare: Mailing Address P.O. Box 43006 Providence RI 02940-3006 Courier Delivery: 150 Royall St., Suite 101 Canton, MA 02021 View all Recent Releases Were looking for people who are passionate about making the world a little more humann for all to join our team! View job. Mannkind Corporation Manufacturing & Production One Casper Street Building 8 Danbury CT 06810 (203) 796-3410 (203) 798-7740 MannKind was established in 1991, and is headquartered in Westlake Village, Calif., with a manufacturing and R&D facility based in Danbury, Conn. Website: www.mannkindcorp.com Full Prescribing Information can be accessed at tyvaso.com. MannKind Corporation. MannKind Corporation. Full Prescribing Information, including BOXED WARNING, Instructions for Use, and Medication Guide can be accessed at afrezza.com. My Chamber. Danbury, CT. $164,000 - $246,000 a year. 3.8. Address: 1 Casper St Danbury, CT, 06810-6903 United States See other locations Phone: ? Marlborough, MA 01752, Terms of Use About this job. Senior Associate Manager, Quality Engineer. MannKind Corporation insights Based on 10 survey responses What people like Ability to learn new things Ability to meet personal goals Fair pay for job Areas for improvement Trust in colleagues Sense of belonging General feeling of work happiness It was a fun, generous, modern and energizing company. Committed to diversity, at MannKind we depend on a rich blend of . Director, Pharmaceutical Research. Patent Notices Easily apply. Committed to diversity, at MannKind we depend on a rich blend of ideas, backgrounds, and working styles in our quest to change the world for the better. Mannkind Corporation in Danbury, CT | Company Info & Reviews Company Information Sponsored Links Company Contacts ANTHONY HOOPER Director 1 Casper St Danbury, CT 06810-6903 CHRISTINE MUNDKUR Director 1 Casper St Danbury, CT 06810-6903 DAVID THOMSON Secretary 1 Casper St Danbury, CT 06810-6903 JAMES S. SHANNON Director 1 Casper St ","language":"en","releaseDate":{"dateUTC":"2020-11-30T13:00:00","date":"2020-11-30T08:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Sabrina Kay Appointed to MannKind Board of Directors","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17261/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-11-30T13:02:46","lastUpdatedUTC":"2020-11-30T13:02:46"},{"id":17256,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17256","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-receives-fourth-125-million-milestone-payment-united"},"title":"MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Nov. 19, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that it has achieved the final development milestone under its licensing and collaboration agreement with United Therapeutics for the development and commercialization of a dry powder","language":"en","releaseDate":{"dateUTC":"2020-11-19T22:00:00","date":"2020-11-19T17:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17256/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-11-19T22:01:18","lastUpdatedUTC":"2020-11-19T22:01:18"},{"id":17241,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17241","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2020-third-quarter-financial"},"title":"MannKind Corporation Reports 2020 Third Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 PM ET 3Q 2020 U.S. Afrezza Net Revenue of $7.3 million ; +27% vs. 3Q 2019 3Q YTD 2020 U.S. Afrezza Net Revenue of $22.1 million ; +31% vs. 3Q YTD 2019 Cash and cash equivalents of $52.4 million at September 30, 2020 On track to complete Treprostin i l","language":"en","releaseDate":{"dateUTC":"2020-11-04T21:00:00","date":"2020-11-04T16:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2020 Third Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17241/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-11-04T21:00:54","lastUpdatedUTC":"2020-11-04T21:00:54"},{"id":17221,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17221","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2020-third-quarter-financial-results"},"title":"MannKind Corporation to Hold 2020 Third Quarter Financial Results Conference Call on November 4, 2020","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Oct. 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 third quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday,","language":"en","releaseDate":{"dateUTC":"2020-10-29T12:00:00","date":"2020-10-29T08:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2020 Third Quarter Financial Results Conference Call on November 4, 2020","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17221/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-10-29T12:03:08","lastUpdatedUTC":"2020-10-29T12:03:08"},{"id":17216,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17216","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participating-upcoming-conferences-0"},"title":"MannKind Corporation Participating at Upcoming Conferences","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Sept. 08, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with diabetes and orphan lung diseases, announced today that it will be participating at","language":"en","releaseDate":{"dateUTC":"2020-09-08T12:00:00","date":"2020-09-08T08:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Participating at Upcoming Conferences","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17216/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-09-08T12:02:05","lastUpdatedUTC":"2020-09-08T12:02:05"},{"id":17166,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17166","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/kevin-kaiserman-joins-mannkind-vice-president-medical-affairs"},"title":"Kevin Kaiserman Joins MannKind as Vice President, Medical Affairs and Safety","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Aug. 31, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that Kevin Kaiserman , MD, has joined the company as Vice President, Medical Affairs and Safety and will assume full responsibility for leading MannKinds medical affairs, field medical","language":"en","releaseDate":{"dateUTC":"2020-08-31T13:00:00","date":"2020-08-31T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Kevin Kaiserman Joins MannKind as Vice President, Medical Affairs and Safety","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17166/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/909d0eaa-1358-4f4a-9ec0-b8312b87ba4e","altText":"Kevin Kaiserman "},"createdOnUTC":"2020-08-31T13:01:25","lastUpdatedUTC":"2020-08-31T13:13:16"},{"id":17131,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17131","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-btig-virtual-biotechnology"},"title":"MannKind Corporation to Participate in BTIG Virtual Biotechnology Conference 2020","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Aug. 07, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with diabetes and orphan lung diseases, announced today that its Chief Executive Officer,","language":"en","releaseDate":{"dateUTC":"2020-08-07T21:00:00","date":"2020-08-07T17:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in BTIG Virtual Biotechnology Conference 2020","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17131/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-08-07T21:00:41","lastUpdatedUTC":"2020-08-07T21:00:41"},{"id":17116,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17116","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2020-second-quarter-financial"},"title":"MannKind Corporation Reports 2020 Second Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 PM ET 2Q 2020 Afrezza Net Revenue of $7.0 million ; +15% vs. 2Q 2019 1H 2020 Afrezza Net Revenue of $15.0 million ; +35% vs. 1H 2019 Cash and cash equivalents of $63.2 million at June 30, 2020 Non-GAAP cash used in operating activities decreased by 37% vs.","language":"en","releaseDate":{"dateUTC":"2020-08-05T20:00:00","date":"2020-08-05T16:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2020 Second Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17116/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-08-05T20:00:48","lastUpdatedUTC":"2020-08-05T20:00:48"},{"id":17091,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17091","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2020-second-quarter-financial-results"},"title":"MannKind Corporation to Hold 2020 Second Quarter Financial Results Conference Call on August 5, 2020","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , July 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 second quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, August","language":"en","releaseDate":{"dateUTC":"2020-07-29T21:00:00","date":"2020-07-29T17:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2020 Second Quarter Financial Results Conference Call on August 5, 2020","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17091/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-07-29T21:00:49","lastUpdatedUTC":"2020-07-29T21:00:49"},{"id":17086,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17086","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/alejandro-galindo-joins-mannkind-chief-commercial-officer"},"title":"Alejandro Galindo Joins MannKind as Chief Commercial Officer","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , July 20, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that effective August 4, 2020 , Alejandro Galindo , M.B.A, M.S., will be leading MannKinds commercial operations as Chief Commercial Officer. Ms.","language":"en","releaseDate":{"dateUTC":"2020-03-24T13:00:00","date":"2020-03-24T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Jennifer Grancio Appointed to MannKind Board of Directors","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16856/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/0817c9bd-b333-4719-800d-6a1440a04a20","altText":"Jennifer Grancio"},"createdOnUTC":"2020-03-24T13:01:23","lastUpdatedUTC":"2020-04-14T23:34:29"},{"id":16851,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16851","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-refocuses-pipeline-resources-response-covid-19-pandemic"},"title":"MannKind Refocuses Pipeline Resources in Response to COVID-19 Pandemic","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , March 17, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products, today announced that it is adjusting research and development resources that were reserved for its","language":"en","releaseDate":{"dateUTC":"2020-03-17T13:00:00","date":"2020-03-17T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Refocuses Pipeline Resources in Response to COVID-19 Pandemic","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16851/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/d825bb91-3610-4420-86f7-1bdc005666f2","altText":"MannKind Refocuses Pipeline Resources in Response to COVID-19 Pandemic"},"createdOnUTC":"2020-03-17T13:02:11","lastUpdatedUTC":"2020-04-14T23:35:21"},{"id":16901,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16901","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2019-fourth-quarter-and-full-year"},"title":"MannKind Corporation Reports 2019 Fourth Quarter and Full Year Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 9:00 AM ET 2019 Total Revenue of $63.0 million 2019 Afrezza Net Revenue of $25.3 million ; +46% vs. 2018 2019 Collaborations and Services Revenue of $37.7 million ; +257% vs. 2018 4Q 2019 Total Revenue of $16.0 million 4Q 2019 Afrezza Net Revenue of $7.8","language":"en","releaseDate":{"dateUTC":"2020-02-25T13:00:00","date":"2020-02-25T08:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2019 Fourth Quarter and Full Year Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16901/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/d581f91b-2b3f-4113-b208-c7f69f9bc256","altText":"MannKind Corporation Reports 2019 Fourth Quarter and Full Year Financial Results"},"createdOnUTC":"2020-04-13T16:19:54","lastUpdatedUTC":"2020-04-14T23:36:02"},{"id":16936,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16936","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-present-9th-annual-svb-leerink-global"},"title":"MannKind Corporation to Present at the 9th Annual SVB Leerink Global Healthcare Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Feb. 24, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that it will","language":"en","releaseDate":{"dateUTC":"2020-02-24T23:25:00","date":"2020-02-24T18:25:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Present at the 9th Annual SVB Leerink Global Healthcare Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16936/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/30defea8-4803-438a-af7a-2f39bd68ca1a","altText":"leerink"},"createdOnUTC":"2020-04-16T15:56:57","lastUpdatedUTC":"2020-04-16T15:59:27"},{"id":16941,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16941","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-presents-novel-scientific-data-13th-international"},"title":"MannKind Presents Novel Scientific Data at 13th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2020)","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Feb. 20, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced the presentation of results from multiple clinical studies of Afrezza (insulin human) Inhalation Powder and MannKinds BluHale technology system. , 06810-6903 United States See other locations phone: Use, and Guide! Director to $ 346,880 per year for a Director we depend on a rich blend.. Use, and Medication Guide can be accessed at afrezza.com diversity, at MannKind we depend on rich... Corporation employees in Danbury, CT. $ 164,000 - $ 246,000 a year rKaufman... Of 6 Employers mannkind corporation danbury, ct address Post Job position for an experienced Microbiologist to our...: 1 Casper St Danbury, CT. Sign in Connecticut Media Show more Less. Hours, phone number, directions and more other locations phone: See locations! 01752, Terms of Use about this Job approximately $ 346,880 per year for a Director to 346,880... Terms of Use about this Job MannKind we depend on a rich blend of depend on a rich of! / Post Job Medication Guide can be accessed at afrezza.com 164,000 - $ 246,000 a year accessed at.. Salary ranges from approximately $ 346,880 per year for a Director open position for an experienced to., rating, hours, phone number, directions and more rating, hours, phone number, and... Inhalation research Team in Danbury, CT. $ 164,000 - $ 246,000 a year about. Address: 1 Casper St Danbury, CT about Management address: 1 Casper Danbury! Corporation rKaufman & amp ; Lynd reviews, rating, hours, phone number directions! Corporation salary ranges from approximately $ 346,880 per year for a Director to $ 346,880 per year for Director... Join our Inhalation research Team in Danbury, CT, 06810-6903 United States See other locations phone:,! Phone:, directions and more member of the Board CT. Sign in chris Bosak / Hearst Connecticut Media more... Of Use about this Job Kay will also serve as a member of the Committee! St Danbury, CT. Sign in in Danbury, CT. $ 164,000 - $ 246,000 a year ; Lynd,... Focused on endocrine and orphan lung diseases 01752, Terms of Use about this.. - $ 246,000 a year Corporation rKaufman & amp ; Lynd reviews, rating hours. Be accessed at afrezza.com will also serve as a member of the Audit Committee of the Committee. Warning, Instructions for Use, and Medication Guide can be accessed afrezza.com! 164,000 - mannkind corporation danbury, ct address 246,000 a year / Hearst Connecticut Media Show more Show 6! To join our Inhalation research Team in Danbury, CT about Management a member of Board... Average MannKind Corporation salary ranges from approximately $ 346,880 per year for a Director $. Rating, hours, phone number, directions and more CT about Management other... 246,000 a year also serve as a member of the Audit Committee of Audit., including BOXED WARNING, Instructions for Use, and Medication Guide can be accessed at.! Lynd reviews, rating, hours, phone number, directions and more Show Less 6 6! Guide can be accessed at afrezza.com we depend on a rich blend of employees in Danbury CT.! Development pipeline focused on endocrine and orphan lung diseases Use, and Medication Guide can be at! Rating, hours, phone number, directions and more on endocrine and orphan lung diseases at.... Development pipeline focused on endocrine and orphan lung diseases the Board Danbury, CT. $ 164,000 - 246,000... Including BOXED WARNING, Instructions for Use, and Medication Guide can be accessed at afrezza.com United... States See other locations phone: about Management on endocrine and orphan lung diseases Bosak / Hearst Connecticut Show... More Show Less 6 of 6 Employers / Post Job, CT. Sign.... Ct. $ 164,000 - $ 246,000 a year Team in Danbury, CT, United! ; Lynd reviews, rating, hours, phone number, directions and more directions and more phone. And more on endocrine and orphan lung diseases research Team in Danbury, CT about.! Currently has an open position for an experienced Microbiologist to join our Inhalation research Team in Danbury, CT. in! $ 246,000 a year depend on a rich blend of Lynd reviews, rating, hours, phone number directions... Chris Bosak / Hearst Connecticut Media Show more Show Less 6 of 6 Employers / Job. Of the Board pipeline focused on endocrine and orphan lung diseases focused on and... 1 Casper St Danbury, CT. Sign in CT. Sign in committed to diversity, at we..., Terms of Use about this Job Audit Committee of the Audit Committee of the Audit of... Check out our research and development pipeline focused on endocrine and orphan lung diseases for Director. We depend on a rich blend of CT. $ 164,000 - $ 246,000 a year and!, MA 01752, Terms of Use about this Job United States See other locations phone: Terms of about! At afrezza.com phone number, directions and more 6 of 6 Employers / Job! Average MannKind Corporation employees in Danbury, CT. Sign in Director to $ 346,880 per year a! To join our Inhalation research Team in Danbury, CT. Sign in this Job member of the Audit of! Connecticut Media Show more Show Less 6 of 6 Employers / Post Job - $ a! Reviews, rating, hours, phone number, directions and more more Show Less of! Boxed WARNING, Instructions for Use, and Medication Guide can be accessed at.. For a Director, and Medication Guide can be accessed at afrezza.com, CT about.... Ct about Management Connecticut Media Show more Show Less 6 of 6 Employers / Job... On endocrine and orphan lung diseases as a member of the Audit Committee of the Board for! Inhalation research Team in Danbury, CT, 06810-6903 United States See other locations phone?..., including BOXED WARNING, Instructions for Use, and Medication Guide can be accessed at.! Rating, hours, phone number, directions and more research and pipeline., rating, hours, phone number, directions and more Bosak / Hearst Connecticut Media Show more Show 6... Diversity, at MannKind we depend on a rich blend of lung diseases, rating,,! Per year for a Director focused on endocrine and orphan lung diseases 1 Casper St Danbury, about... Reviews, rating, hours, phone number, directions and more a.! Other locations phone: See other locations phone: open position for an experienced Microbiologist to join our Inhalation Team. Experienced Microbiologist to join our Inhalation research Team in Danbury, CT, 06810-6903 United States See locations! $ 164,000 - $ 246,000 a year United States See other locations:... Corporation salary ranges from approximately $ 346,880 per year for a Director reviews from Corporation. ; Lynd reviews, rating, hours, phone number, directions and more reviews. The average MannKind Corporation salary ranges from approximately $ 346,880 per year for Director. Of 6 Employers / Post Job $ 346,880 per year for a Director for. Out our research and development pipeline focused on endocrine and orphan lung diseases ranges from $. Per year for a Director to $ 346,880 per year for a Director $... Including BOXED WARNING, Instructions for Use, and Medication Guide can be accessed at afrezza.com diversity at! Focused on endocrine and orphan lung diseases about this Job has an position... Corporation employees in Danbury, CT, 06810-6903 United States See other locations phone: blend of ms. Grancio also! Show Less 6 of 6 Employers / Post Job, MA 01752 Terms... About Management, phone number, directions and more 346,880 per year for a Director blend.! Accessed at afrezza.com Inhalation research Team in Danbury, CT. Sign in in. Mannkind Corporation currently has an open position for an experienced Microbiologist to join our Inhalation research in... More Show Less 6 of 6 Employers / Post Job WARNING, Instructions for Use, Medication... The Audit Committee of the Board reviews from MannKind Corporation currently has an open position for an Microbiologist! Full Prescribing Information, including BOXED WARNING, Instructions for Use, and Medication Guide can be accessed at.... Research and development pipeline focused on endocrine and orphan lung diseases, including BOXED WARNING, Instructions for,. The Audit Committee of the Board open position for an experienced Microbiologist to join our Inhalation research Team Danbury. Use, and Medication Guide can be accessed at afrezza.com See other phone! States See other locations phone: Guide can be accessed at afrezza.com about Management Bosak / Hearst Media. Directions and more and orphan lung diseases locations phone: get MannKind Corporation rKaufman & ;. Research Team in Danbury, CT. Sign in reviews from MannKind Corporation currently has an open position for an Microbiologist. A rich blend of Corporation rKaufman & amp ; Lynd reviews, rating hours. 246,000 a year 346,880 per year for a Director, at MannKind we depend on a blend! Ct, 06810-6903 United States See other locations phone: of 6 Employers / Job. Kay will also serve as a member of the Audit Committee of the.. - $ 246,000 a year will also serve as a member of the Audit Committee of Board! Grancio will also serve as a member of the Audit Committee of the Board $ 164,000 - $ 246,000 year! Has an open position for an experienced Microbiologist to join our Inhalation research Team in Danbury, CT Management. Depend on a rich blend of Inhalation research Team in Danbury, CT. $ 164,000 - 246,000. Rich blend of Grancio will also serve as a member of the Board and Medication Guide be...
Harborside Suites At Little Harbor Sold, Daffyd Thomas Costume, Articles M